DDRE-34. TARGETING RESISTANCE IN MEDULLOBLASTOMA
نویسندگان
چکیده
منابع مشابه
Targeting the Hedgehog Pathway in Pediatric Medulloblastoma
Medulloblastoma (MB), a primitive neuroectomal tumor of the cerebellum, is the most common malignant pediatric brain tumor. The cause of MB is largely unknown, but aberrant activation of Hedgehog (Hh) pathway is responsible for ~30% of MB. Despite aggressive treatment with surgical resection, radiation and chemotherapy, 70%-80% of pediatric medulloblastoma cases can be controlled, but most trea...
متن کاملIDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma
Medulloblastoma (MB) is the most common malignant brain tumor in children. Despite therapeutic advancements, high-risk groups still present significant mortality. A deeper knowledge of the signaling pathways contributing to MB formation and aggressiveness would help develop new successful therapies. The target of rapamycin, mTOR signaling, is known to be involved in MB and is already targetable...
متن کاملOvercoming multiple drug resistance mechanisms in medulloblastoma
INTRODUCTION Medulloblastoma (MB) is the most common malignant paediatric brain tumour. Recurrence and progression of disease occurs in 15-20% of standard risk and 30-40% of high risk patients. We analysed whether circumvention of chemoresistance pathways (drug export, DNA repair and apoptotic inhibition) can restore chemotherapeutic efficacy in a panel of MB cell lines. RESULTS We demonstrat...
متن کاملTargeting the PI3K/AKT/mTOR signaling pathway in medulloblastoma.
Medulloblastoma is the most common malignant childhood brain tumor and is associated with a poor outcome. There is an urgent need to develop novel targeted therapeutic approaches for medulloblastoma, which will arise from an enhanced understanding of the disease at the molecular level. Medulloblastoma has been recognized to be a heterogeneous disease, and no recurrent cancer gene mutations have...
متن کاملTargeting Resistance
Wrestling with cancer can be frustrating. Despite the progress in developing therapies that can effectively control tumor growth, the devil almost always strikes back with resistance. Even for the recent excitement in using immunotherapy to achieve unprecedented success in some cancer patients, resistance has been seen in clinical settings and is under active investigation (Restifo et al., 2016...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology Advances
سال: 2021
ISSN: 2632-2498
DOI: 10.1093/noajnl/vdab024.056